Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2019

Every FDA drug recall initiated in 2019, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

1,788 recalls, newest first.

Class II · Moderate risk

Dextroamphetamine Sacharate

Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness.

Terminated Wrong potency / content Aurobindo Pharma USA Inc. NDC 13107-073-01 D-0143-2020
Class II · Moderate risk

Losartan Potassium/ Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0124-2020
Class II · Moderate risk

Losartan Potassium /Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0123-2020
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0122-2020
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0121-2020
Class II · Moderate risk

Lidocaine Hydroclhoride Jelly USP

cGMP Deviations: firm reported finding metal particulate matter in the filling room near the tube feeder during the filling operation of the product. No particulates were identified in the product, but rather were identified on the filling line.

Terminated Particulate / foreign matter Akorn, Inc. NDC 17478-711-30 D-1878-2019
Class III · Low risk

Sodium Chloride Injection USP 0.9%

Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.

Terminated Labeling / mix-up Guerbet LLC NDC 0019-1188-27 D-0138-2020
Class II · Moderate risk

Optiray 320

Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.

Terminated Labeling / mix-up Guerbet LLC NDC 0019-1323-00 D-0137-2020
Class II · Moderate risk

Fentanyl Citrate USP

CGMP Deviations: Received notice from supplier that there is potential glass contamination.

Terminated cGMP deviation Spectrum Laboratory Products NDC 49452-0032-06 D-0141-2020

Recalls by year